PagerDuty, Inc.(PD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PD PagerDuty, Inc.

休市中 12-12 16:00:00 EST

13.00

-0.03

-0.23%

盘后12.95

-0.05-0.38%

18:38 EST

最高13.14	最低12.93	成交量138.41万
今开13.05	昨收13.03	日振幅1.61%
总市值11.93亿	流通市值11.35亿	总股本9,178万
成交额1,802万	换手率1.59%	流通股本8,727万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PD","market":"US","secType":"STK","nameCN":"PagerDuty, Inc.","latestPrice":13,"timestamp":1765573200000,"preClose":13.03,"halted":0,"volume":1384059,"hourTrading":{"tag":"盘后","latestPrice":12.95,"preClose":13,"latestTime":"18:38 EST","volume":118554,"amount":1541109.591,"timestamp":1765582683409},"delay":0,"floatShares":87273400,"shares":91776804,"eps":1.62968,"marketStatus":"休市中","change":-0.03,"latestTime":"12-12 16:00:00 EST","open":13.05,"high":13.14,"low":12.93,"amount":18018409.461093,"amplitude":0.016117,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.62968,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1554955200000,"exchange":"NYSE","adjPreClose":13.03,"preHourTrading":{"tag":"盘前","latestPrice":13,"preClose":13.03,"latestTime":"09:22 EST","volume":2776,"amount":36465.283384,"timestamp":1765549361721},"postHourTrading":{"tag":"盘后","latestPrice":12.95,"preClose":13,"latestTime":"18:38 EST","volume":118554,"amount":1541109.591,"timestamp":1765582683409},"volumeRatio":0.6071163282545264,"impliedVol":0.5225,"impliedVolPercentile":0.38},"requestUrl":"/m/hq/s/PD","defaultTab":"news","newsList":[{"id":"2590504741","title":"产业新闻 | FDA授予百时美施贵宝PD-1疗法组合优先审评资格；创新帕金森病免疫疗法积极试验结果公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2590504741","media":"药明康德","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590504741?lang=zh_cn&edition=full","pubTime":"2025-12-12 08:00","pubTimestamp":1765497601,"startTime":"0","endTime":"0","summary":"FDA授予百时美施贵宝PD-1疗法组合优先审评资格百时美施贵宝今日宣布，美国FDA已受理Opdivo的补充生物制品许可申请，用于与多柔比星、长春花碱和达卡巴嗪联合，治疗既往未接受治疗的III期或IV期经典型霍奇金淋巴瘤成人及儿童患者。FDA授予该申请优先审评资格，并将PDUFA日期确定为2026年4月8日。此次FDA受理及优先审评的决定，主要基于3期SWOG S1826研究的积极结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212092546a443889e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212092546a443889e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1670710588.SGD","LU1032466523.USD","LU0882574055.USD","LU0985481810.HKD","IE0002141913.USD","IE00BJJMRZ35.SGD","LU1868837300.USD","LU1989771016.USD","IE0009355771.USD","LU0868494617.USD","LU0321505439.SGD","LU1430594728.SGD","LU1868837136.USD","PD","IE00BSNM7G36.USD","IE00BJT1NW94.SGD","LU1718418525.SGD","LU2125154935.USD","LU0267386448.USD","LU2133065610.SGD","LU2242652126.USD","IE00B2B36J28.USD","LU1670711123.USD","BK4532","BK4581","LU1093756325.SGD","LU0114720955.EUR","BK4534","LU1868836591.USD","BMY","IE00BFTCPJ56.SGD","LU0096364046.USD","LU1169590202.USD","LU2242646821.SGD","LU0321505868.SGD","LU1585245621.USD","BK4588","IE00BFXG1179.USD","BK4007","BK4023","LU1261432733.SGD","LU1670711040.USD","LU1323610961.USD","LU1291159041.SGD","LU0456855351.SGD","LU1571399168.USD","LU2360032135.SGD","LU1169589451.USD","BK4585","LU1868836757.USD"],"gpt_icon":0},{"id":"2590563981","title":"港股异动 | 荣昌生物(09995)盘中涨超7% 公布PD-1/VEGF双抗非小细胞肺癌临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2590563981","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590563981?lang=zh_cn&edition=full","pubTime":"2025-12-11 10:45","pubTimestamp":1765421137,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，荣昌生物盘中涨超7%，截至发稿，涨5.57%，报81.5港元，成交额3.1亿港元。会上，由荣昌生物自主研发的PD-1/VEGF双特异性抗体RC148单药及联合方案一线或二线治疗非小细胞肺癌的一项Ⅰ/Ⅱ期临床研究数据，以壁报形式正式发布。据悉，今年8月，RC148已获FDA批准在美国开展II期临床试验。获得FDA的IND许可，标志着该药将进入全球临床开发阶段。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380238.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1169589451.USD","LU2328871848.SGD","BK1574","BK1161","LU1969619763.USD","LU2488822045.USD","LU1064131003.USD","LU2148510915.USD","PD","09995","LU1169590202.USD","BK0239","LU1064130708.USD","688331","BK4023","BK1583"],"gpt_icon":0},{"id":"2589801094","title":"和誉-B(02256)：和誉医药于ESMO Asia 2025公布口服PD-L1抑制剂ABSK043联合 EGFR抑制剂伏美替尼治疗NSCLC的II期临床初步结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2589801094","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589801094?lang=zh_cn&edition=full","pubTime":"2025-12-08 08:06","pubTimestamp":1765152368,"startTime":"0","endTime":"0","summary":"数据显示，ABSK043与伏美替尼的“靶免联合”方案展现出良好的安全性和耐受性。研究结果显示，ABSK043联合伏美替尼表现出可控的安全性和良好的耐受性。剂量递增阶段的研究结果表明，ABSK043联合伏美替尼不仅安全性可控、耐受性良好，还展现出令人鼓舞的初步抗肿瘤活性。上述积极结果为正在开展的剂量扩展阶段奠定了基础，该阶段将评估ABSK043联合伏美替尼作为一线疗法，用于治疗初治的EGFR突变、PD-L1阳性的NSCLC患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378554.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B5MMRT66.SGD","09939","LU2778985437.USD","BK1515","BK1574","IE00BPRC5H50.USD","LU2476274308.USD","LU2476274720.SGD","LU1169590202.USD","PD","LU1169589451.USD","LU2488822045.USD","02256","159938","BK4023","BK1161","IE00B543WZ88.USD"],"gpt_icon":0},{"id":"2589289437","title":"ADC药物与PD-1/VEGF双抗联用再添案例 科伦博泰与Crescent达成双向授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2589289437","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589289437?lang=zh_cn&edition=full","pubTime":"2025-12-05 19:52","pubTimestamp":1764935561,"startTime":"0","endTime":"0","summary":"12月4日，科伦博泰（HK06990）与CrescentBiopharma,Inc.（一家纳斯达克上市公司，以下简称Crescent）共同宣布，双方已建立战略合作伙伴关系。科伦博泰方面将ADC药物（抗体偶联药物）SKB105在中国以外权利授权Crescent，并预计将获得最高超13亿美元的授权收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512053584015760.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512053584015760.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ADC","BK4080","LU1169590202.USD","PD","BK4023","BK4231","LU1169589451.USD"],"gpt_icon":0},{"id":"2589865213","title":"ADC与PD-1红海之外，宝济药业如何找到生物医药的“第二增长曲线”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2589865213","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589865213?lang=zh_cn&edition=full","pubTime":"2025-12-05 13:33","pubTimestamp":1764912788,"startTime":"0","endTime":"0","summary":"而在ADC、PD-1等热门靶点赛道数百家企业拥挤厮杀，从临床入组速度到未来的市场定价无不白热化的竞争中，上海宝济药业股份有限公司选择了一条截然不同的差异化战略路径。与传统疗法相比，KJ103的革命性优势则在于其“快”。目前，其领先地位和临床价值已获得监管机构的高度认可。对于KJ017而言，其市场空间并不取决于自身的销量，而是与整个千亿级生物药市场的增长深度绑定，其商业模式堪称典型的“卖水人”逻辑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378061.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["399441","LU1169590202.USD","02659","ADC","BK4080","LU1169589451.USD","PD","161726","BK4023","BK4231"],"gpt_icon":1},{"id":"2588709367","title":"复宏汉霖PD-L1 ADC II期结果读出；*ST苏吴进入退市整理期｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2588709367","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588709367?lang=zh_cn&edition=full","pubTime":"2025-12-02 07:01","pubTimestamp":1764630081,"startTime":"0","endTime":"0","summary":"丨2025年12月2日星期二丨NO.1复宏汉霖PD-L1ADCII期结果读出11月26日，复宏汉霖发布公告表示将在ESMOAsia2025大会上公布多项药物的临床数据。亮点之一在于核心资产PD-L1ADC药物HLX43在宫颈癌领域的II期研究结果。点评：针对PD-L1ADC开发在研管线并不多，目前进度最快的是辉瑞的PF-08046054，已至临床III期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512023579600777.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512023579600777.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0060","600200","PD","BK4080","BK0012","BK0239","BK0188","BK4231","159938","BK0028","BK1515","BK1574","09939","BK1161","LU1169590202.USD","02696","LU1169589451.USD","BK4023","HK0000165453.HKD","ADC"],"gpt_icon":0},{"id":"1169730844","title":"异动解读 | PagerDuty盘中大跌16.96%，CFO退休计划及下调年度收入预期引发市场担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1169730844","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169730844?lang=zh_cn&edition=full","pubTime":"2025-11-26 22:34","pubTimestamp":1764167674,"startTime":"0","endTime":"0","summary":"PagerDuty（股票代码：PD）今日盘中股价大幅下跌16.96%，成为市场关注的焦点。消息面上，公司首席财务官Owen Howard Wilson于11月22日通知公司，他计划在公司任命继任者后退休。这一突如其来的高管变动引发了投资者对公司财务管理连续性的担忧，导致股价承压。此外，PagerDuty还下调了其26财年的收入预期，从原先的4.93-4.97亿美元下调至4.9-4.92亿美元。公司表示，这一调整是由于定价和市场过渡的影响。市场普遍认为，这一负面预期进一步加剧了投资者的抛售情绪。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PD"],"gpt_icon":0},{"id":"1175428775","title":"异动解读 | PagerDuty盘前大跌5.8%，CFO退休计划引发投资者担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1175428775","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175428775?lang=zh_cn&edition=full","pubTime":"2025-11-26 17:14","pubTimestamp":1764148457,"startTime":"0","endTime":"0","summary":"PagerDuty, Inc.（股票代码：PD）今日盘前股价大跌5.8%，引发了市场的广泛关注。消息面上，公司首席财务官Owen Howard Wilson于11月22日通知公司，他计划在公司任命继任者后退休。这一突如其来的人事变动可能引发了投资者对公司财务管理连续性的担忧，从而导致股价下跌。CFO的离职通常会对公司产生重大影响，尤其是在没有明确继任计划的情况下。投资者可能担心这一变动会影响PagerDuty的财务策略和执行能力。市场将密切关注公司未来的公告，以评估这一人事变动对长期发展的影响。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PD"],"gpt_icon":0},{"id":"1188385986","title":"异动解读 | PagerDuty夜盘大跌6.13%，CFO退休计划引发投资者担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1188385986","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188385986?lang=zh_cn&edition=full","pubTime":"2025-11-26 12:36","pubTimestamp":1764131803,"startTime":"0","endTime":"0","summary":"PagerDuty, Inc.（股票代码：PD）今日夜盘股价大跌6.13%，引发了市场的广泛关注。消息面上，公司首席财务官Owen Howard Wilson于11月22日通知公司，他计划在公司任命继任者后退休。这一突如其来的人事变动可能引发了投资者对公司财务管理连续性的担忧，从而导致股价下跌。CFO的离职通常会对公司产生重大影响，尤其是在没有明确继任计划的情况下。投资者可能担心这一变动会影响PagerDuty的财务策略和执行能力。市场将密切关注公司未来的公告，以评估这一人事变动对长期发展的影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PD"],"gpt_icon":0},{"id":"1138300127","title":"异动解读 | PagerDuty股价盘后大跌7.11%，CFO宣布退休计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1138300127","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138300127?lang=zh_cn&edition=full","pubTime":"2025-11-26 05:32","pubTimestamp":1764106356,"startTime":"0","endTime":"0","summary":"PagerDuty, Inc.今日盘后股价大跌7.11%，引发市场关注。据悉，PagerDuty首席财务官Owen Howard Wilson于11月22日通知公司，他计划在公司任命继任者后退休。CFO的离职通常会对公司产生重大影响，尤其是在没有明确继任计划的情况下。投资者可能担心这一变动会影响PagerDuty的财务策略和执行能力。市场将密切关注PagerDuty在未来几周内的进一步公告，以评估这一人事变动对公司长期发展的潜在影响。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["PD"],"gpt_icon":0},{"id":"1107419902","title":"PagerDuty- 11月22日，Owen Howard Wilson 通知其计划在公司任命继任者后退休，担任首席财务官","url":"https://stock-news.laohu8.com/highlight/detail?id=1107419902","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107419902?lang=zh_cn&edition=full","pubTime":"2025-11-26 05:13","pubTimestamp":1764105189,"startTime":"0","endTime":"0","summary":"PagerDuty- 11月22日，Owen Howard Wilson 通知其计划在公司任命继任者后退休，担任首席财务官","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169589451.USD","LU1169590202.USD","BK4023","PD"],"gpt_icon":0},{"id":"2584618171","title":"复星医药(600196.SH)：斯鲁利单抗纳入突破性治疗药物程序 全球范围内尚无靶向PD-1的单抗药品获批用于胃癌新辅助/辅助治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2584618171","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584618171?lang=zh_cn&edition=full","pubTime":"2025-11-20 16:57","pubTimestamp":1763629023,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 复星医药(600196.SH)发布公告，根据国家药品监督管理局(以下简称“国家药监局”)药品审评中心公示信息，公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司自主研发的斯鲁利单抗注射液(中国境内1商品名：汉斯状®;以下简称“该药品”)用于联合化疗新辅助/辅助治疗胃癌(GCneo)已被纳入突破性治疗药物程序。该药品为集团自主研发的创新型抗 PD-1 单抗。截至本公告日期，全球范围内尚无靶向PD-1的单克隆抗体药品获批用于胃癌新辅助/辅助治疗。根据IQVIA MIDAS™最新数据，2024年，靶向PD-1的单克隆抗体药品于全球的销售额约为457.04亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1371586.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","BK0187","BK1515","LU1169590202.USD","BK4023","BK1191","PD","BK0028","BK0096","02196","BK0188","BK0060","BK1593","600196","BK0175","LU1169589451.USD","BK0012","BK0239","BK0196"],"gpt_icon":0},{"id":"2584818419","title":"招商证券：首予三生制药（01530）“强烈推荐”评级 PD-1/VEGF双抗引领价值重估","url":"https://stock-news.laohu8.com/highlight/detail?id=2584818419","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584818419?lang=zh_cn&edition=full","pubTime":"2025-11-20 16:32","pubTimestamp":1763627548,"startTime":"0","endTime":"0","summary":"三生制药与辉瑞达成重磅授权协议，将SSGJ-707的全球权益授予辉瑞，辉瑞将支付14亿美元前端付款+48亿美元里程碑付款+1亿美元股份认购，创国产PD-(L)1/VEGF双抗BD纪录","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20251120/20251120163345_97955.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20251120/20251120163345_97955.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1371561.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["01530","PD","06099"],"gpt_icon":0},{"id":"2584984363","title":"泽璟制药(688266.SH)：注射用ZG006与PD-1/PD-L1免疫检查点抑制剂及化疗(依托泊苷/卡铂)联用获得药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2584984363","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584984363?lang=zh_cn&edition=full","pubTime":"2025-11-18 15:50","pubTimestamp":1763452203,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泽璟制药 发布公告，公司于近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，注射用ZG006与PD-1/PD-L1免疫检查点抑制剂及化疗联合用于小细胞肺癌的临床试验获得批准。ZG006 是一种针对两个不同 DLL3 表位及CD3的三特异性T细胞衔接器。临床前研究结果显示，ZG006在小鼠肿瘤模型上具有显著的肿瘤抑制作用，可以导致显著比例的小鼠肿瘤完全消退，说明ZG006 具有强效的肿瘤杀伤作用。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1370470.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PD","BK4023","BK0239","688266","LU1169589451.USD","LU1169590202.USD"],"gpt_icon":0},{"id":"2581038400","title":"复宏汉霖PD-L1 ADC肺癌新药发布关键数据，CEO朱俊：定位PD-1 联用的super ADC","url":"https://stock-news.laohu8.com/highlight/detail?id=2581038400","media":"蓝鲸财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581038400?lang=zh_cn&edition=full","pubTime":"2025-11-06 10:36","pubTimestamp":1762396614,"startTime":"0","endTime":"0","summary":"近日，HLX43肺癌关键数据更新发布，首次合并NSCLC II期国际多中心临床研究结果，全球临床价值持续验证。他表示，复宏汉霖至少会开8个III期临床项目，预计会包括两个一线，四个二线，以及两个三线，而这8个III期临床都会集中在肺癌。业内认为，复宏汉霖估值上行的关键在于其自研PD-L1抗体偶联药物HLX43的全球潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1762338933079134283","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["PD","LU1169589451.USD","BK4080","ADC","LU1169590202.USD","02696","BK4231","BK4023","BK1161"],"gpt_icon":1},{"id":"2581779683","title":"PD-L1 ADC肺癌数据积极 复宏汉霖HLX43迎关键节点与资金考验","url":"https://stock-news.laohu8.com/highlight/detail?id=2581779683","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581779683?lang=zh_cn&edition=full","pubTime":"2025-11-05 22:31","pubTimestamp":1762353115,"startTime":"0","endTime":"0","summary":"在近日举行的“2025国际肺癌前沿及创新论坛”上，复宏汉霖更新了HLX43在非小细胞肺癌（NSCLC）研究领域的关键数据。研究数据显示，不论是在鳞状还是非鳞状NSCLC，无论EGFR突变状态、是否伴有脑转移或PD-L1表达水平如何，HLX43均观察到疗效信号。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511053556160251.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511053556160251.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02696","LU1169590202.USD","LU1169589451.USD","BK4080","BK4231","BK4023","ADC","PD","BK1161"],"gpt_icon":0},{"id":"2580227234","title":"基石药业-B(02616)宣布CS2009(PD-1/VEGF/CTLA-4三特异性抗体)Ⅱ期临床试验联合疗法IND在中国获批，深入探索三抗治疗潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2580227234","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580227234?lang=zh_cn&edition=full","pubTime":"2025-11-04 08:05","pubTimestamp":1762214718,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 发布公告，该公司今日宣布CS2009联合疗法用于晚期实体瘤的Ⅱ 期新药临床试验申请获中国国家药品监督管理局批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364784.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4023","LU1169589451.USD","LU1169590202.USD","BK1161","02616","BK1574","PD"],"gpt_icon":0},{"id":"2580966482","title":"三生国健(688336.SH)：辉瑞在某网站上登记PD-1/VEGF双抗PF-08634404(SSGJ-707)的两项全球III期临床试验其最终付款尚存在不确定性","url":"https://stock-news.laohu8.com/highlight/detail?id=2580966482","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580966482?lang=zh_cn&edition=full","pubTime":"2025-11-03 18:25","pubTimestamp":1762165505,"startTime":"0","endTime":"0","summary":"智通财经APP讯，三生国健 发布股价异动公告称，公司及三生制药和沈阳三生共同授予被许可方辉瑞公司在许可区域及领域的独家开发、生产和商业化许可产品707项目的权利。《许可协议》于2025年7月24日正式生效。2025年10月30日，辉瑞在ClinicalTrials.gov网站上登记了PD-1/VEGF双抗PF-08634404的两项全球III期临床试验。鉴于《许可协议》中所约定的里程碑付款需要满足一系列特定条件，其最终付款尚存在不确定性，敬请广大投资者注意投资风险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364589.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1057294990.SGD","LU0170899867.USD","IE00B19Z3581.USD","IE00BLSP4239.USD","SG9999002224.SGD","SGXZ57979304.SGD","IE00B19Z3B42.SGD","SG9999001176.USD","BK4533","LU0306806265.USD","BK4550","III","LU0225284248.USD","BK4581","LU0122379950.USD","LU0225771236.USD","BK0239","LU1066053197.SGD","PD","LU0289739699.SGD","SG9999013999.USD","688336","LU1883839398.USD","BK4023","SG9999003800.SGD","BK4592","IE00BBT3K403.USD","SG9999002232.USD","LU1066051498.USD","BK4534","LU0306807586.USD","LU0456855351.SGD","LU1894683264.USD","SG9999001176.SGD","LU1023059063.AUD","LU0868494617.USD","BK4568","LU0058720904.USD","LU0321505439.SGD","LU0985481810.HKD","BK4007","LU1169590202.USD","BK4134","LU0321505868.SGD","BK4585","LU1169589451.USD","LU0234572021.USD","IE000M9KFDE8.USD","LU1894683348.USD"],"gpt_icon":0},{"id":"2580887230","title":"和誉-B(02256)完成口服小分子PD-L1抑制剂ABSK043联合戈来雷塞治疗NSCLC II期临床首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2580887230","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580887230?lang=zh_cn&edition=full","pubTime":"2025-11-03 08:13","pubTimestamp":1762128819,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B 发布公告，2025年11月3日，和誉医药宣布，其口服小分子PD-L1抑制剂ABSK043与上海艾力斯医药科技股份有限公司(艾力斯) KRAS G12C抑制剂戈来雷塞联合用于治疗携带KRAS G12C突变的非小细胞肺癌的II期临床研究已完成首例患者给药。本项开放标签II期临床研究，旨在评估ABSK043联合戈来雷塞治疗携带KRAS G12C突变的局部晚期或转移性NSCLC患者的安全性、耐受性及有效性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364210.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2488822045.USD","02256","PD","LU1169590202.USD","LU1169589451.USD","BK1161","BK4023"],"gpt_icon":0},{"id":"2577367573","title":"PD-(L)1/VEGF赛道攻坚，依沃西冲击首个海外适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2577367573","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577367573?lang=zh_cn&edition=full","pubTime":"2025-10-22 11:58","pubTimestamp":1761105514,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者韩利明当地时间10月20日，SummitTherapeutics（纳斯达克股票代码：SMMT）在2025年三季度财报中宣布，将于2025年第四季度向美国食品药品监督管理局（FDA）提交依沃西单抗联合化疗的生物制品许可申请（BLA），用于治疗经第三代EGFR-TKI治疗进展的EGFR突变非鳞状非小细胞肺癌（NSCLC）患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202510223540978275.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510223540978275.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1169590202.USD","PD","LU1169589451.USD","LU2487616109.SGD","LU0053666078.USD","BK4585","BK4588","LU0210528500.USD","BK4023","BK4107","L"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pagerduty.com","stockEarnings":[{"period":"1week","weight":0.0586},{"period":"1month","weight":-0.187},{"period":"3month","weight":-0.2092},{"period":"6month","weight":-0.096},{"period":"1year","weight":-0.3583},{"period":"ytd","weight":-0.2881}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"PagerDuty, Inc.于2010年5月根据特拉华州法律注册成立。PagerDuty是数字企业的中枢神经系统。PagerDuty利用几乎任何支持软件的系统或设备的数字信号，将其与人工响应数据相结合，并协调团队实时采取正确的行动。公司的产品可帮助组织改善运营，加速创新，增加收入，降低安全风险并提供出色的客户体验。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.045759},{"month":2,"riseRate":0.5,"avgChangeRate":-0.032478},{"month":3,"riseRate":0.5,"avgChangeRate":-0.018297},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.049825},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.007313},{"month":6,"riseRate":0.714286,"avgChangeRate":0.021791},{"month":7,"riseRate":0.571429,"avgChangeRate":0.017838},{"month":8,"riseRate":0.571429,"avgChangeRate":-0.000522},{"month":9,"riseRate":0,"avgChangeRate":-0.114196},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.036422},{"month":11,"riseRate":0.571429,"avgChangeRate":0.021164},{"month":12,"riseRate":0.571429,"avgChangeRate":0.041265}],"exchange":"NYSE","name":"PagerDuty, Inc.","nameEN":"PagerDuty, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"PagerDuty, Inc.(PD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供PagerDuty, Inc.(PD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"PagerDuty, Inc.,PD,PagerDuty, Inc.股票,PagerDuty, Inc.股票老虎,PagerDuty, Inc.股票老虎国际,PagerDuty, Inc.行情,PagerDuty, Inc.股票行情,PagerDuty, Inc.股价,PagerDuty, Inc.股市,PagerDuty, Inc.股票价格,PagerDuty, Inc.股票交易,PagerDuty, Inc.股票购买,PagerDuty, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"PagerDuty, Inc.(PD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供PagerDuty, Inc.(PD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}